U.S. patent application number 16/613743 was filed with the patent office on 2020-03-05 for skin dullness suppressing agent, and skin barrier function maintaining or improving agent.
The applicant listed for this patent is EZAKI GLICO CO., LTD.. Invention is credited to Haruyo SAMBE, Kazuhisa SUGIMOTO.
Application Number | 20200069568 16/613743 |
Document ID | / |
Family ID | 64274165 |
Filed Date | 2020-03-05 |
United States Patent
Application |
20200069568 |
Kind Code |
A1 |
SUGIMOTO; Kazuhisa ; et
al. |
March 5, 2020 |
SKIN DULLNESS SUPPRESSING AGENT, AND SKIN BARRIER FUNCTION
MAINTAINING OR IMPROVING AGENT
Abstract
Provided is a novel agent containing a plant-derived component,
which has an effect against the dullness of the skin and an effect
against the deterioration of a skin barrier function. A skin
dullness suppressing agent or a skin barrier function maintaining
or improving agent, which contains an oil-soluble extract derived
from red paprika. It is preferred that the skin dullness
suppressing agent or the skin barrier function maintaining or
improving agent has a dosage form of an oral preparation, and it is
also preferred that the oil-soluble extract contains a
hexane-soluble component.
Inventors: |
SUGIMOTO; Kazuhisa;
(Osaka-shi, Osaka, JP) ; SAMBE; Haruyo;
(Osaka-shi, Osaka, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
EZAKI GLICO CO., LTD. |
Osaka-shi, Osaka |
|
JP |
|
|
Family ID: |
64274165 |
Appl. No.: |
16/613743 |
Filed: |
May 15, 2018 |
PCT Filed: |
May 15, 2018 |
PCT NO: |
PCT/JP2018/018632 |
371 Date: |
November 14, 2019 |
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61Q 19/00 20130101;
A61K 36/81 20130101; A61K 8/9789 20170801; A61P 17/00 20180101;
A61Q 17/00 20130101 |
International
Class: |
A61K 8/9789 20060101
A61K008/9789; A61Q 19/00 20060101 A61Q019/00; A61Q 17/00 20060101
A61Q017/00 |
Foreign Application Data
Date |
Code |
Application Number |
May 15, 2017 |
JP |
2017-096146 |
Claims
1. A skin dullness suppressing agent comprising an oil-soluble
extract from red paprika.
2. The skin dullness suppressing agent according to claim 1,
wherein the skin dullness suppressing agent has a dosage form of an
oral preparation.
3. The skin dullness suppressing agent according to claim 1,
wherein the oil-soluble extract contains a hexane-soluble
component.
4. A skin barrier function maintaining or improving agent
comprising an oil-soluble extract from red paprika.
5. The skin barrier function maintaining or improving agent
according to claim 4, wherein the skin barrier function maintaining
or improving agent has a dosage form of an oral preparation.
6. The skin barrier function maintaining or improving agent
according to claim 4, wherein the oil-soluble extract contains a
hexane-soluble component.
7. A method of preparing a skin dullness suppressing agent
comprising obtaining an oil-soluble extract from red paprika.
8. A method of preparing a skin barrier function maintaining or
improving agent comprising obtaining an oil-soluble extract from
red paprika.
Description
TECHNICAL FIELD
[0001] The present invention relates to a skin dullness suppressing
agent and a skin barrier function maintaining or improving agent.
More specifically, the present invention relates to a skin dullness
suppressing agent and a skin barrier function maintaining or
improving agent, each of which contains an extract from red
paprika.
BACKGROUND ART
[0002] The dullness of the skin is a phenomenon which occurs in the
skin with ageing, and it is considered that the dullness of the
skin is caused by combined effects of various factors such as the
cloudiness or shading of the skin due to the thickening of a
stratum corneum, the decrease in redness of the skin and the
increase in yellowness of the skin, in the dull skin, the decrease
in lightness is observed.
[0003] As a skin tone improving agent for improving the dullness of
the skin, Patent Document 1 describes an oral preparation
containing crocetin or a pharmacologically acceptable salt thereof
as the active ingredient. Crocetin, which is the active ingredient
of the oral preparation, can be produced by, for example, the
extraction from a dried gardenia fruit with an ethanol-water mixed
solution.
[0004] The deterioration in the skin barrier function is a
phenomenon which often occurs in skin having various skin diseases
or aged skin, and it is considered that the deterioration in the
skin barrier function is caused by, for example, the structural or
compositional defects of a stratum corneum for functioning the
stratum corneum as a barrier. In the skin having deteriorated skin
barrier function, the increase in the transepidermal loss of water
contained in a lower layer of a stratum corneum is observed.
[0005] As a skin barrier function promotor, Patent Document 2
describes an external preparation containing one or both of
tocopherol and a glyceride having a specified structure and
astaxanthin. Astaxanthin to be contained in the external
preparation can be produced, for example, as a Haematococcus algae
extract.
[0006] As mentioned above, various attempts to use a plant-derived
natural component as an active ingredient of a cosmetic have been
made so far. On the other hand, a cosmetic utilizing a component
derived from chili pepper (Capsium annum L.) is also known.
[0007] For example, Patent Document 3 discloses a fermented
composition containing a fermented product of chili pepper or a
capsinoid-containing plant or an extract from the fermented
product. It is described that the fermented composition is
preferably a fermented product of a non-pungent cultivar of chili
pepper such as CH-19 sweet and can be used as an anti-fatigue
agent, a physical strength increasing agent, an anti-obesity agent,
an anti-oxidant agent, a skin beautifying agent, a skin whitening
agent and a flavor improving agent.
[0008] Patent Document 4 describes a cosmetic composition
containing an aqueous distillate produced by distilling at least
one solanaceous plant selected from chili pepper and others with
water vapor. It is described that the cosmetic composition can
specifically improve dried skin and impart glow and elasticity to
the skin.
[0009] Patent Document 5 describes a skin whitening cosmetic
composition containing, as an active ingredient, at least one
extract selected from an extract from wood ear mushroom that
belongs to the family Auriculariaceae, an extract from Japanese
horseradish (wasabi) that belongs to the family Brassicaceae, an
extract from chili pepper that belongs to the family Solanaceae and
an extract from buckwheat that belongs to the family Polygonaceae.
In the skin whitening cosmetic composition, the extract from chili
pepper that belongs to the family Solanaceae is produced from chili
pepper which has been used as a spice, more specifically green
chili pepper.
PRIOR ART DOCUMENTS
Patent Documents
[0010] Patent Document 1: Japanese Patent Laid-open Publication No.
2014-19692
[0011] Patent Document 2: International Publication No.
2011/074275
[0012] Patent Document 3: Japanese Patent Laid-open Publication No.
2005-161
[0013] Patent Document 4: Japanese Patent Laid-open Publication No.
2001-226219
[0014] Patent Document 5: Japanese Patent Laid-open Publication No.
H5-163135
SUMMARY OF THE INVENTION
Problem to be Solved by the Invention
[0015] In the fermented composition disclosed in Patent Document 3,
the pungent taste or acridity of the capsaicinoid is reduced and
amino acids and vitamins are enriched by fermenting the raw
material. As described in Comparative Examples 1 and 2 and others
in Patent Document 3, the composition which is not fermented cannot
achieve the desired effect. CH-19 sweet, which is a raw material
that is confirmed to have the effect in Patent Document 3. is a
kind of green non-pungent chili pepper.
[0016] In the cosmetic composition disclosed in Patent Document 4,
an aqueous distillate produced by the distillation of chili pepper
with water vapor is contained. Therefore, the active ingredient of
the cosmetic composition is a water-soluble component among
components derived from chili pepper. Furthermore, in the cosmetic
composition, it is unknown as to whether the chili pepper is of a
pungent ty or a non-pungent type or whether the chili pepper is red
chili pepper or green chili pepper.
[0017] In the skin whitening cosmetic composition disclosed in
Patent Document 5, the active ingredient which is confirmed to have
a skin whitening effect is an extract from green pungent chili
pepper.
[0018] As described in Patent Documents 3 to 5, among components
derived from chili pepper, a component derived from green chili
pepper, a water-soluble component and/or a fermented component is
actually confirmed to have an effect against the skin. The chemical
composition of a component derived from chili pepper greatly varies
depending on the type of the chili pepper, the extraction solvent
to be used, the presence or absence of a fermentation treatment,
and the like. With respect to components other than the
above-mentioned components among the components derived from chili
pepper, there is found no report about the fact that these
components inspected cosmetically. Furthermore, it is impossible to
estimate as to whether or not these components have an effect
against the dullness and an effect against the skin barrier
function which are described in Patent Documents 1 and 2.
[0019] A main object of the present invention is to provide a novel
plant-derived component-containing preparation having an effect
against the dullness of the skin and an effect against a skin
barrier function.
Means for Solving the Problem
[0020] As the result of the intensive and extensive studies, the
present inventors have found that an oil-soluble extract from red
paprika has an effect against the dullness of the skin and an
effect against a skin barrier function. The present invention has
accomplished by making further studies on the basis of this
finding.
[0021] The present invention provides the following aspects of
inventions.
[0022] 1. A skin dullness suppressing agent including an
oil-soluble extract from red paprika.
[0023] 2. The skin dullness suppressing agent according to item 1,
in which the skin dullness suppressing agent has a dosage form of
an oral preparation.
[0024] 3. The skin dullness suppressing agent according to item or
2, in which the oil-soluble extract contains a hexane-soluble
component.
[0025] 4. A skin barrier function maintaining or improving agent
including an oil-soluble extract from red paprika.
[0026] 5. The skin barrier function maintaining or improving agent
according to item 4, in which the skin barrier function maintaining
or improving agent has a dosage form of an oral preparation.
[0027] 6. The skin barrier function maintaining or improving agent
according to item 4 or 5, in which the oil-soluble extract contains
a hexane-soluble component.
[0028] 7. A use of an oil-soluble extract from red paprika for
production of a skin dullness suppressing agent.
[0029] 8. A use of an oil-soluble extract from red paprika for
production of a skin barrier function maintaining or improving
agent.
Advantages of the Invention
[0030] According to the present invention, a novel plant-derived
component-containing preparation having an effect against the
dullness of the skin and an effect against a skin barrier function
is provided.
EMBODIMENTS OF THE INVENTION
[0031] [1. Suppression of Dullness of Skin]
[0032] In a skin dullness suppressing agent according to the
present invention, the term "skin dullness" (also simply referred
to as "dullness", hereinafter) refers to a condition of the skin
where the lightness of the skin is decreased. The dullness is
caused by the thickening of a stratum corneum, the detachment of a
stratum corneum, the deterioration in elasticity of the skin, the
decrease in redness of skin tone, the increase in yellowness of
skin tone and the like, and the mechanisms of action of these
phenomena are different from the mechanism of action of
pigmentation which is caused by the stimulation of a melanin
cell.
[0033] In the dull skin, skin phenomena such as the decrease in
transparency of the skin (turbidness of the skin), the decrease in
glow of the skin (cloudiness of the skin) and the deposition of
dirt such as sweat and sebum are observed. Examples of the factor
that can cause the dullness include aging, environmental changes
(including variation in atmospheric temperature, decrease in
humidity and the like). These factors are often correlated with
each other. Under the same environmental change, for example, the
dullness suppressing effect of the dullness suppressing agent
according to the present invention can be exerted more
advantageously against more aged skin (e.g., skin of a 40-year-old
or older person).
[0034] The dullness can be evaluated by measuring skin lightness
(an L value). The skin lightness may decrease with the progression
of dullness, while the skin lightness may increase with the
improvement of dullness. The term "suppression of dullness" refers
to an effect to fight back against the progression of dullness, and
includes, for example, an effect to reduce the degree of decrease
in skin lightness and an effect to maintain skin lightness both
under a condition where dullness can be caused as well as an effect
to increase skin lightness.
[0035] [2. Maintenance or Improvement of Skin Barrier Function]
[0036] With respect to the skin barrier function maintaining or
improving agent according to the present invention, the term "skin
barrier function" refers to a function produced as the result of
the adhesion of a corneocyte to a horny layer intercellular lipid
in a stratum corneum or the like. The skin phenomenon that the skin
barrier function is deteriorated is caused as the result of the
disorder of the arrangement of corneocytes due to the deterioration
in adhesion between the corneocytes and a horny layer intercellular
lipid or the like, and the mechanism of action thereof is different
from that of the deterioration in the proliferation function of
fibroblasts and is also different from that of sunburn-induced
transient inflammation,
[0037] In the skin having deteriorated skin barrier function, the
water loss from an under layer of a stratum corneum increases to
increase the sensitivity to an external stimulus. As a result, a
skin phenomenon such as roughening of skin, rash and itching is
observed. As the factors that can cause the deterioration in skin
barrier function, aging, environmental changes (including variation
in atmospheric temperature, decrease in humidity and the like),
stress, an environmental pollutant and the like can be mentioned.
These factors are often correlated with each other. The skin
barrier function maintaining or improving effect by the skin
barrier function maintaining or improving agent according to the
present invention can be exerted more advantageously against the
skin of a person in a younger to middle age group (e.g., a person
of 30 years of age or older and 40 years of age or younger) who is
especially sensitive to a factor that may cause the deterioration
in a skin barrier function.
[0038] The skin barrier function can be evaluated in terms of a
transepidermal water loss (TEWL). When the skin barrier function is
deteriorated, the transepidermal water loss tends to he increased.
When the skin barrier function is improved, in contrast, the
transepidermal water loss tends to be decreased. The term
"maintenance or improvement in skin barrier function" refers to an
effect to prevent the deterioration of skin barrier function, and
includes, for example, an effect to reduce the degree of increase
in transepidermal water loss and an effect to maintain
transepidermal water loss both under a condition where the
deterioration in skin barrier function can be caused as well as an
effect to decrease transepidermal water loss.
[0039] [3. Extract from Red Paprika]
[0040] Each of the skin dullness suppressing agent and the skin
barrier function maintaining or improving agent according to the
present invention contains an oil-soluble extract derived from red
paprika as an active ingredient. The extract from red paprika is an
extract produced by carrying out an extraction treatment of red
paprika.
[0041] [3.1 Raw Materials]
[0042] Red paprika is a plant belonging to the family Solanaceae,
the genus Capsicum. Red paprika is specifically Capsicum annuum,
more specifically Capsicum annuum L., still more specifically
Capsicum annuum L. var. grossium. Among the above-mentioned plants,
red paprika is a non-pungent cultivar of chili pepper having a red
color. The cultivar, the production area and the like of red
paprika are not particularly limited. Examples of the cultivar of
red paprika include bell-shaped paprika, ramyuro-type paprika, and
wedge-shaped paprika (palermo). From the viewpoint of the
production efficiency of the extract, a cultivar having a smaller
water content (e.g., wedge-shaped paprika such as palermo) is
preferred.
[0043] The extraction part in red paprika is not particularly
limited, as long as at least a fruit pulp part is contained.
Examples of another part that is acceptable as the extraction part
include a seed, a flower, a stem, a leaf and a rhizome. From the
viewpoint of advantageously achieving the dullness suppressing
performance and skin barrier function maintaining or improving
performance, it is preferred that the extraction part is
substantially only a fruit pulp part. In the production of the
extract, the extraction part in red paprika may be used without any
modification, or may be used in a pretreated state, for example
such a state that the part is milled or finely cut in advance or
the part is dried and then is milled or finely cut.
[0044] [3-2. Extraction]
[0045] The extraction method is not particularly limited, as long
as an organic solvent is used as the extraction solvent. The
organic solvent may be any one of a non-polar solvent, a polar
aprotic solvent and a polar protic solvent. Examples of the
non-polar solvent include: a hydrocarbon-type solvent such as
hexane (e.g., n-hexane, cyclohexane) and toluene, preferably hexane
(n-hexane, cyclohexane), particularly preferably n-hexane; an
ether-type solvent such as dimethyl ether and diethyl ether; a
halogenated hydrocarbon-type solvent such as chloroform, methylene
chloride and trichloroethylene; and an ester-type solvent such as
ethyl acetate. An example of the polar aprotic solvent is a
ketone-type solvent such as acetone. An example of the polar protic
solvent is an alcohol-type solvent such as methanol, ethanol,
n-propanol and isopropanol, preferably ethanol.
[0046] The above-mentioned organic solvents may he used singly, or
a combination of two or more of them may be used. From the
viewpoint of advantageously achieving the dullness suppressing
performance and the skin barrier function maintaining or improving
performance, the organic solvent may contain at least a non-polar
solvent, preferably a hydrocarbon-type solvent, more preferably
n-hexane, in an amount of, for example, 1 to 100% by volume,
preferably 30 to 100% by volume, therein.
[0047] From the viewpoint of concentration efficiency, the organic
solvent may have a boiling point of 80.degree. C. or lower,
preferably 70.degree. C. or lower.
[0048] With respect to the extraction operation, it may be
possible, for example, to immerse red paprika in the organic
solvent by cold immersion, hot immersion or the like, and
optionally stir or homogenize the immersed product to thereby elute
an active ingredient in the organic solvent. Examples of the
organic solvent include hexane, acetone and ethanol. From the
viewpoint of the extraction efficiency and the achievement of the
dullness suppressing performance and the skin barrier function
maintaining or improving performance, it is preferred to use at
least hexane. The conditions to be employed for the elution are not
particularly limited. The amount of the organic solvent is 1- to
20-fold weight, preferably 2- to 10-fold weight, in terms of a dry
weight of the extraction part, the temperature is, for example,
10.degree. C. to 50.degree. C., preferably 20.degree. C. to
30.degree. C., and the time is 1 hour to 72 hours, preferably 4
hours to 48 hours.
[0049] The organic solvent fraction can he separated by
solid-liquid separation. The method for the separation is not
particularly limited, and may be selected appropriately from a
column separation method, a filtration method and a centrifugal
separation method. The separated organic solvent fraction may be
concentrated by removing a portion or the whole of the organic
solvent. A liquid concentrate thus produced or a concentrate that
is a dried product of the liquid concentrate can be obtained as the
red paprika extract. The dried product can be obtained by a drying
treatment such as concentration to dryness, atomization to dryness
and lyophilization. The red paprika extract may be produced by
further carrying out a purification treatment or a separation
treatment of a highly active fraction, as required. Examples of the
purification treatment include treatments such as filtration,
adsorption (e.g., an ion exchange resin column, an activated carbon
column). Examples of the treatment for the separation of the highly
active fraction include gel filtration, an adsorption treatment,
silica gel column chromatography and HPLC.
[0050] From the viewpoint of achieving the dullness suppressing
performance and the skin barrier function maintaining or improving
performance, the extract does not undergo a decomposition treatment
such as fermentation. Furthermore, it is preferred that the extract
does not undergo any treatment accompanied by chemical change other
than a decomposition treatment, either.
[0051] [3-3. Components]
[0052] Since the raw material for the extract according to the
present invention is red paprika which is non-pungent chili pepper,
a pungent component is not contained in a substantial amount (i.e.,
an amount at which a pungent flavor or irritation can be produced
as in the case of a pungent chili pepper component). An example of
the pungent component is a capsaicinoid contained in pungent chili
pepper, more specifically capsaicin, dihydrocapsaicin,
nordihydrocapsaicin, homocapsaicin, homodihydrocapsaicin or the
like.
[0053] Furthermore, the red paprika extract is oil-soluble. The
term "oil-soluble" as used herein refers to a property to be
insoluble in water. The oil-soluble extract should contain a
component soluble in an organic solvent. Examples of the organic
solvent are those organic solvents which are mentioned above as the
extraction solvents. Therefore, examples of the component soluble
in the organic solvent include: a component soluble in a non-polar
solvent, including a component soluble in a hydrocarbon-type
solvent such as hexane (e.g., n-hexane, cyclohexane) and toluene,
preferably hexane (n-hexane, cyclohexane), particularly preferably
n-hexane, a component soluble in an ether-type solvent such as
dimethyl ether and diethyl ether, a component soluble in a
halogenated hydrocarbon-type solvent such as chloroform, methylene
chloride and trichloroethylene, and a component soluble in an
ester-type solvent such as ethyl acetate; a component soluble in a
polar aprotic solvent, including a component soluble in a
ketone-type solvent such as acetone; and a component soluble in a
polar protic solvent, including a component soluble in an
alcohol-type solvent such as methanol, ethanol, n-propanol,
isopropanol, preferably ethanol.
[0054] In the above-mentioned oil-soluble extract, the
above-mentioned soluble components may be contained singly or two
or more of them may be contained in combination. From the viewpoint
of advantageously achieving the dullness suppressing performance
and the skin barrier function maintaining or improving performance,
it is preferred to contain at least a component soluble in a
non-polar solvent, preferably a component soluble in a
hydrocarbon-type solvent, more preferably a component soluble in
hexane, particularly preferably a component soluble in n-hexane,
among the above-mentioned soluble components.
[0055] More specific examples of the component to be contained in
the oil-soluble extract include xanthophyll and .beta.-carotene.
Examples of the xanthophyll include capsanthin, cucurbitaxanthin A,
.beta.-cryptoxanthin, zeaxanthin, capsanthin 3, 6-epoxide,
capsorubin, cryptocapsin and derivatives thereof. An example of the
derivative is a fatty acid ester. A specific example of the fatty
acid ester is an ester of a saturated or saturated fatty acid
having 12 to 22 carbon atoms such as lauric acid, myristic acid,
palmitic acid, stearic acid and oleic acid.
[0056] From the viewpoint of achieving the dullness suppressing
performance and the skin barrier function maintaining or improving
performance, the oil-soluble extract may have a color value
(E.sup.10%.sub.1cm) of, for example, 300 to 3500, preferably 1000
to 3500. In the present invention, the terms "color value
(E.sup.10%.sub.1cm)" refers to a numerical value determined by
measuring an absorbance at a maximum absorption wavelength (460 nm)
in a visible part of an acetone solution containing an oil-soluble
extract of interest and then converting the absorbance to an
absorbance of a 10-w/v % acetone solution.
[0057] [4. Dullness Suppressing Agent and Skin Barrier Function
Maintaining or Improving Agent]
[0058] The skin dullness suppressing agent or the skin barrier
function maintaining or improving agent should contain at least the
above-mentioned oil-soluble extract. The skin dullness suppressing
agent and the skin barrier function maintaining or improving agent
may be prepared in the form of a composition that further contains
an additive suitable for a dosage form capable of being applied to
a living body.
[0059] [4.1 Application Embodiments]
[0060] Examples of the application embodiments of the dullness
suppressing agent or the skin barrier function maintaining or
improving agent include an external preparation for skin, an oral
preparation, a transvenous preparation, a transarterial
preparation, a subcutaneous preparation and an intramuscular
preparation. Among these application embodiments, an external
preparation for skin and an oral preparation are preferred, and an
oral preparation is more preferred from the viewpoint of
convenience and the efficient achievement of the dullness
suppressing performance or the skin barrier function maintaining or
improving performance.
[0061] [4.2 Subject to be Applied]
[0062] Examples of the subject to be applied with the dullness
suppressing agent according to the present invention include a
subject who has an awareness of dullness and needs to be suppressed
from the progression of dullness or needs to be improved in
dullness, and a subject who needs to be prevented from dullness.
The subject to be applied with the dullness suppressing agent is
preferably a subject in an older age group, more specifically a
subject of 40 years of age or older.
[0063] Examples of the subject to be applied with the skin barrier
function maintaining or improving agent according to the present
invention include a subject who has an awareness of the
deterioration in a skin barrier function and needs to be suppressed
from the deterioration in a skin barrier function or needs to be
improved in the deterioration in a skin barrier function, and a
subject who needs to be prevented from the deterioration in a skin
barrier function. The subject to be applied with the skin barrier
function maintaining or improving agent is preferably a subject in
a younger to middle age group who is especially sensitive to a
factor that can cause the deterioration in a skin barrier function,
more specifically a subject of 30 years of age or older and 40
years of age or younger.
[0064] [4.3 Appearance]
[0065] Examples of the appearance of the dullness suppressing agent
and the skin barrier function maintaining or improving agent
include a solid form (e.g., a powdery form, a granular form, a
tablet), a liquid form (e.g., a form prepared by dissolving or
dispersing in an oil, water or another solvent), and a semi-solid
form (e.g., a gel-like form, an ointment-like form and a paste-like
form prepared by dispersing in an oil, water or another
solvent).
[0066] [4.4 External Preparation for Skin]
[0067] In an external composition for skin to be used as an
external preparation for skin, a pharmacologically,
cosmetologically and pharmaceutically acceptable additive may be
added. The additive may be selected depending on the type of the
preparation form and the formulation form, and examples of the
additive include an excipient, a thickening agent, a tonicity
agent, a pH adjuster, a stabilizing agent, an antiseptic agent, a
preservative agent, a dispersing agent, an emulsifying agent, a
gelatinizing agent, a pigment and a perfume material. Examples of
the type of the preparation form include a liquid oil form, an
emulsion form, a powdery form, a powder dispersion form, a gel
form, an ointment form, an aerosol form, a water-oil bilayer form,
and a water-oil-powder trilayer form. The formulation form of the
external composition for skin is not particularly limited, as long
as the formulation form can be applied transepidermally, and
examples of the formulation form include a drug for external
application to skin, a quasi-drug for external application to skin,
a cosmetic and a skin cleanser. More specific examples of the
formulation form include: a drug for external application to skin,
such as a cream, a lotion, a gel, an emulsion, a solution, an
adhesive patch, an aerosol, an ointment and a pack; a quasi-drug
for external application to skin, such as a cream, a lotion, a gel,
an emulsion, a solution, an adhesive patch, an aerosol, an ointment
and a pack; a cosmetic, such as a cream, a lotion, a gel, an
emulsion, a solution, an ointment and a pack and a skin cleanser,
such as body shampoo, hair shampoo and hair conditioner. Among
these formulation forms, a drug for external application to skin is
preferred, and a cream, a lotion, a gel, an emulsion or a pack is
more preferred.
[0068] The amount (in terms of a dry weight) of the oil-soluble
extract to be contained in 100% by mass of the dullness suppressing
agent and the skin function maintaining or improving agent to be
used as an external composition for skin (external preparation) may
be, for example, 0.005% by mass to 100% by mass, preferably 0.02%
by mass to 100% by mass. In the present invention, the term "a
value in terms of a dry weight" refers to a value of the amount of
the oil-soluble red paprika extract which is determined in terms of
a dry weight (i.e., an amount of a dried solid matter). When other
components such as a solvent and an additive are contained in the
composition, the value corresponds to a weight of the composition
from which the amounts of the above-mentioned other components are
subtracted.
[0069] The amount of the oil-soluble extract in the dullness
suppressing agent and the skin barrier function maintaining or
improving agent to be used as an external composition for skin
(external preparation) may be such an amount that the color value
(E.sup.10%.sub.1cm) of the composition can become 0.1 to 3500,
preferably 0.5 to 3500.
[0070] The dose amount of the dullness suppressing agent and the
skin barrier function maintaining or improving agent to be used as
an external composition for skin (external preparation) may be
adjusted appropriately depending on the type of the preparation
form, the formulation form, the level of the condition of skin to
which the preparation is to be applied and the like. As a specific
example of the dose amount, the agent is applied in a single dose
or about several divided doses per day in such an amount that, for
example, the amount (in terms of a dry weight) of the oil-soluble
extract can become 0.1 .mu.g to 6 .mu.g/dose, preferably 0.4 .mu.g
to 3 .mu.g/dose, per 1 cm.sup.2 of skin.
[0071] As another specific example of the dose amount of the
dullness suppressing agent and the skin barrier function
maintaining or improving agent to be used as an external
composition for skin (external preparation), the agent is applied
in a single dose or about several divided doses per day in such an
amount that the total color value amount
((E.sup.10%.sub.1cm).times.weight (g)) can become, for example,
0.0004 to 0.02/dose, preferably 0.001 to 0.008/dose, per 1 cm.sup.2
of skin.
[0072] [4.5 Oral Preparation]
[0073] Examples of the oral composition to be used as an oral
preparation include foods and beverages, including a health food, a
functional food, a dietary supplement and a food for specified
health use. In the oral composition, a food-hygienically acceptable
additive may be added. Examples of the additive include; a
sweetener such as glucose, sucrose, fructose, high-fructose corn
syrup, aspartame and stevia; an acidulant such as citric acid,
malic acid and tartaric acid; an excipient such as dextrin and
starch; a binder; a diluent such as an oil and a fat; a flavoring
material; a coloring agent; a buffering agent; a thickening agent;
a gelatinizing agent; a stabilizing agent; a preservative agent; an
emulsifying agent; a dispersing agent; a suspending agent; and an
antiseptic agent. Examples of the dosage form of the dullness
suppressing agent and the skin barrier function maintaining or
improving agent to be used as an oral composition include; a
supplement such as tablets, hard capsules and soft capsules;
various beverages (e.g., a refreshing beverage, a carbonated
beverage, a beauty drink, a nutritional beverage, a fruit beverage,
a milk beverage); an original liquid concentrate or an instant
powder for each of these beverages; an oil and a fat, and oil and
fat processed food; and a seasoning agent.
[0074] The amount (in terms of a dry weight) of the oil-soluble
extract to be contained in 100% by mass of the dullness suppressing
agent and the skin barrier function maintaining or improving agent
to be used as an oral composition (oral preparation) may be, for
example, 0.005% by mass to 100% by mass, preferably 0.01% by mass
to 100% by mass.
[0075] The amount of the oil-soluble extract to be contained in the
dullness suppressing agent and the skin barrier function
maintaining or improving agent to be used as an oral composition
(oral preparation) may be such an amount that the color value
(E.sup.10%.sub.1cm) of the composition can become 0.1 to 3500,
preferably 0.2 to 3500.
[0076] The dose amount of the dullness suppressing agent and the
skin barrier function maintaining or improving agent to be used as
an oral composition (oral preparation) may be adjusted
appropriately depending on the type of the preparation form, the
formulation form, the level of the condition of skin to which the
preparation is to be applied and the like. As a specific example of
the dose amount, the agent is applied in a single dose or about
several divided doses per day in such an amount that the amount (in
terms of a dry weight) of the oil-soluble extract can become, for
example, 10 mg to 400 mg/day, preferably 50 mg to 200 mg/day.
[0077] As another specific example of the dose amount of the
dullness suppressing agent and the skin barrier function
maintaining or improving agent to be used as an oral composition
(oral preparation), the agent is applied in a single dose or about
several divided doses per day in such an amount that the total
color value amount ((E.sup.10% .sub.1cm).times.weight (g)) can
become, for example, 30 to 1000/day, preferably 200 to 500/day.
EXAMPLES
Example 1
[0078] As a raw material, 5 g (in terms of dry weight) of red
paprika (palermo, a European cultivar) was provided. The dried red
paprika was cut into fine pieces, then the fine pieces were
immersed in a 6-fold weight of n-hexane at room temperature for 21
hours, and then the resultant solution was filtrated to separate an
n-hexane fraction. n-Hexane was removed by distillation under a
reduced pressure to produce an oily extract. The extract thus
produced had a color value (E.sup.10%.sub.1cm) of 660. The color
value was determined by preparing a solution by diluting the
extract with acetone, then measuring an absorbance of the solution
at a maximum absorption wavelength (460 nm) in a visible part of
the solution using an ultraviolet-visible spectrophotometer (V-650,
manufactured by JASCO Corporation), and then converting the
absorbance to an absorbance of a 10-w/v % acetone solution.
Example 2
[0079] Red paprika extract-containing soft capsules (having a total
color value amount of 270 per capsule) each containing 333 mg of a
commercially available red paprika oil-soluble extract preparation
having a color value of 810 (PapriX; manufactured by Glico
Nutrition Co., Ltd.) were prepared. Forty three normal male and
female persons were divided into a test food ingestion group (22
persons) and a placebo food ingestion group (21 persons). The range
of the ages of the whole population of the forty three normal male
and female persons was 30 to 49 years old, the average of the ages
was 41.1 years old, and the median of the ages was 41 years old. In
the test food ingestion group, the red paprika extract-containing
soft capsules were ingested every day at a dose of 1 capsule/day
over two weeks. In the placebo food ingestion group, soft capsules,
which contained the same components as those of the test food
except that the red paprika extract was not contained, were
ingested every day at a dose of 1 capsule/day over two weeks. This
test was carried out in the autumn season (October) where the
decrease in the atmospheric temperature and the dryness of the air
proceeded. A treatment of forcibly irradiating each of the subjects
with ultraviolet ray was not carried out.
[0080] The lightness (L value) of the left cheek of each of the
subjects was evaluated before and after the ingestion. The L value
was measured by subjecting each of the subjects to face washing in
a room which was conditioned at a room temperature of
21.+-.1.degree. C. and a room temperature of 50.+-.5%, then
allowing each of the subjects to wait for 10 minutes, and then
measuring the lightness of the left cheek of each of the subjects
using a lightness measuring device (a spectrophotometer CM-2600d;
manufactured by Konica Minolta Optics, Inc.). An average value of
the L values measured in each of the test food ingestion group (22
persons) and the placebo food ingestion group (21 persons) before
and after the ingestion was determined. As the evaluation on
effectiveness, the comparison over time in each of the groups
(i.e., within group comparison) was carried out employing paired
t-test.
TABLE-US-00001 TABLE 1 30- to 49-years-old L value Before Two weeks
after ingestion ingestion p Test food (22 persons) 62.76 62.73 No
significant change was observed Placebo food (21 persons) 62.32
62.16 Significant decrease was observed (p < 0.05)* *Compared
before and after ingestion (paired t-test)
[0081] As shown in Table 1, in the placebo food ingestion group,
remarkable and significant decrease in the L value was observed
after the ingestion compared with that before the ingestion
(p<0.05). In contrast, in the test food ingestion group,
significant decrease in the L value was not observed after the
ingestion compared with that before the ingestion. It was shown
that the paprika extract exerted an effect to suppress the decrease
in skin lightness (i.e., the progression of dullness) that was
observed in the placebo ingestion group.
EXAMPLE 3
[0082] Twenty persons (specifically 42- to 49-year-old persons),
who were in an older age group, were selected from the whole
population (43 persons) employed in Example 2, and an average value
of the L values before and after the ingestion was determined in
each of a test food ingestion group (10 persons) and a placebo food
ingestion group (10 persons) in the same manner as in Example 2. As
the evaluation on effectiveness, the comparison over time in each
of the groups (i.e., within group comparison) was carried out
employing paired t-test.
TABLE-US-00002 TABLE 2 42- to 49-years-old L value Before Two weeks
after ingestion ingestion p Test food (10 persons) 61.36 61.38 No
significant change was observed Placebo food (10 persons) 61.79
61.62 Significant decrease was observed (p < 0.05)* *Compared
before and after ingestion (paired t-test)
[0083] As shown in Table 2, when the whole population in Example 2
was narrowed down to an older age group, in the placebo food
ingestion group, the degree of the decrease in the L value after
the ingestion compared with that before the ingestion was expanded
compared with that in Example 2. In the test trod ingestion group,
in contrast, improvement in the L value was observed compared with
that measured before the ingestion. That is, when the whole
population was narrowed down to the older age group, the variation
in the L value was further expanded compared with that in the whole
population employed in Example 2. With respect to the change in the
L value before and after the ingestion, significant decrease
(p<0.05) was confirmed only in the placebo food ingestion group.
From these results, it was demonstrated that the paprika extract
exerted a higher dullness suppressing effect in the persons in the
older age group who were more susceptible to dullness.
Example 4
[0084] A transepidermal water loss (TEWL) before and after the
ingestion was measured in each of the test food ingestion group and
the placebo food ingestion group employed in Example The TEWL value
was determined by subjecting each of the subjects to face washing
in a room which was conditioned at a room temperature of
21.+-.1.degree. C. and a humidity of 50.+-.5%, then allowing each
of the subjects to wait for 10 minutes, and then measuring the
transepidermal water loss on the left cheek of each of the subjects
using a transepidermal water loss measuring device (Vaposcan;
manufactured by Asahi Techno Lab. ltd.).
[0085] An average value of the TEWL values measured before and
after the ingestion in each of the test food ingestion group (22
persons) and the placebo food ingestion group (21 persons) was
determined. As the evaluation on effectiveness, the comparison over
time in each of the groups (i.e., within group comparison) was
carried out employing paired t-test.
TABLE-US-00003 TABLE 3 30- to 49-years-old TEWL value (g/h m.sup.2)
Before Two weeks after ingestion ingestion p Test food (22 persons)
12.51 13.42 No significant change was observed Placebo food (21
persons) 11.44 12.86 Significant decrease was observed (p <
0.05)* *Compared before and after ingestion (paired t-test)
[0086] As shown in Table 3, in the placebo food ingestion group,
remarkable and significant increase in the transepidermal water
loss was observed after the ingestion compared with that before the
ingestion (p<0.05). In contrast, in the test food ingestion
group, significant increase in the transepidermal water loss was
not observed after the ingestion compared with that before the
ingestion. It was shown that the paprika extract exerted an effect
to suppress the deterioration in the skin barrier function which
was observed in the placebo ingestion group.
Example 5
[0087] Twenty persons (30- to 40-year-old persons), who were in a
younger to middle age group, were selected from the whole
population (43 persons) employed in Example 2, and an average value
of the TEWL values before and after the ingestion in each of a test
food ingestion group (it persons) and a placebo food ingestion
group (9 persons) was determined in the same manner as in Example
4. As the evaluation on effectiveness, the comparison over time in
each of the groups (i.e., within group comparison) was carried out
employing paired t-test.
TABLE-US-00004 TABLE 4 30- to 40-years-old TEWL value (g/h m.sup.2)
Before Two weeks after ingestion ingestion p Test food (11 persons)
11.53 11.62 No significant change was observed Placebo food (9
persons) 11.91 14.34 Significant decrease was observed (p <
0.05)* *Compared before and after ingestion (paired t-test)
[0088] As shown in Table 4, when the whole population in Example 2
was narrowed down to the younger to middle age group, in the
placebo food ingestion group, the degree of the increase in the
TEWL value after the ingestion compared with that before the
ingestion was increased compared with that in Example 4. In the
test food ingestion group, in contrast, the degree of the increase
in the TEWL value was decreased compared with that measured before
the ingestion. That is, when the whole population was narrowed down
to the younger to middle age group, the variation in the TEWL value
was further expanded compared with that in the whole population
employed in Example 2. With respect to the change in the TEWL value
before and after the ingestion, a significant difference
(p<0.05) was confirmed only in the placebo food ingestion group.
From these results, it was demonstrated that the paprika extract
exerted a higher skin barrier maintaining or improving effect in
the persons in the younger to middle age group who were
particularly susceptible to a factor involved in the deterioration
in the skin barrier function.
[0089] As in the case of Examples 2 to 5, the red paprika
extract-containing soft capsules (a total color value per capsule:
270) prepared using the red paprika extract color value: 660)
prepared in Example 1 also exerted an effect to suppress the
decrease in skin lightness (i.e., the progression in dullness), a
higher dullness suppressing effect in persons in an older age group
who were more susceptible to dullness, an effect to suppress the
deterioration in the skin barrier function, and a higher skin
barrier maintaining or improving effect in persons in a younger to
middle age group who were particularly susceptible to a factor
involved in the deterioration in the skin barrier function.
[0090] The preferred embodiments of the present invention are as
mentioned above. However, the present invention is not intended to
be limited to these embodiments, and various other embodiments may
be made without departing from the spirit of the invention.
* * * * *